New uremic toxins - which solutes should be removed?

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Toxicology

Background:

• Chronic kidney disease (CKD) is marked by accumulating toxins.
• These toxins, including protein-bound solutes and middle molecules, contribute to cardiovascular damage and mortality in CKD patients.
• Vascular lesions in CKD affect endothelial cells, leukocytes, platelets, and vascular smooth muscle cells.

Purpose of the Study:

• To review the role of specific toxins in CKD-related cardiovascular damage.
• To discuss the limitations of standard dialysis in removing these toxins.
• To explore novel therapeutic strategies for improved CKD patient outcomes.

Main Methods:

• Literature review focusing on protein-bound compounds (indoxylsulfate, p-cresylsulfate) and middle molecules (AGEs, cytokines, dinucleoside polyphosphates).
• Analysis of standard dialysis efficacy for different solute classes.
• Examination of emerging therapeutic approaches like adsorption and pharmacological neutralization.

Main Results:

• Protein-bound solutes and middle molecules are key contributors to vascular damage in CKD.
• Standard dialysis has limited efficacy for removing protein-bound solutes due to their binding.
• Removal of middle molecules can be improved with larger dialyzer pores and convective strategies.

Conclusions:

• Effective removal of specific toxins is crucial for improving cardiovascular outcomes in CKD.
• Novel strategies beyond standard dialysis are needed to manage toxin burden.
• Targeted removal or neutralization of toxins holds promise for better CKD patient management.